Dr. Krueger is head of the Laboratory for Investigative Dermatology at The Rockefeller University in New York City. He also serves as a physician and codirector for the Center for Clinical and Translational Science at The Rockefeller University Hospital in New York as well as chief executive officer of the hospital. He earned his bachelor’s degree from Princeton University and a Ph.D. in virology and cell biology from The Rockefeller University. He received his M.D. from Cornell University Medical College, where he also completed an internship in internal medicine and residency in dermatology. Dr. Krueger is certified by the American Board of Dermatology. His research group at Rockefeller was the first to conduct clinical trials with specific, targeted immune antagonists in psoriasis; this work established that elimination of pathogenic T cells from skin lesions could reverse the full pathological phenotype of psoriasis. Since then, his group has used immune-based therapeutics to dissect inflammatory pathways in psoriasis and to conduct parallel pharmacogenomic studies that define mechanisms of targeted therapeutics in human populations. A more recent focus has been definition of new inflammatory pathways as well as new types of inflammatory cells in psoriasis lesions that are now being targeted with new biologic drugs.